Henan Xinhe Construction Investment Group Co., Ltd. agreed to acquire 60% stake in Xinyang Yuehe Real Estate Co., Ltd. from Henan Lingrui Pharmaceutical Co., Ltd. for approximately CNY 110 million.
January 15, 2017
Share
Henan Xinhe Construction Investment Group Co., Ltd. agreed to acquire 60% stake in Xinyang Yuehe Real Estate Co., Ltd. from Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) for approximately CNY 110 million on January 16, 2017. After completion of the transaction, Henan Lingrui Pharmaceutical Co., Ltd. will hold 40% stake and Henan Xinhe Construction Investment Group Co., Ltd. will hold 60% stake in Xinyang Yuehe Real Estate Co., Ltd.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
Henan Xinhe Construction Investment Group Co., Ltd. agreed to acquire 60% stake in Xinyang Yuehe Real Estate Co., Ltd. from Henan Lingrui Pharmaceutical Co., Ltd. for approximately CNY 110 million.
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 
